Overview

Neuroinflammation in Alzheimer’s Disease describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer’s disease, Parkinson’s disease, and related disorders. ^{1"Microglial phenotypes in AD (2020)"2020 · DOI 10.1016/j.tins.2020.03.002Open reference}

Neuroinflammation is a central pathological feature of Alzheimer’s disease (AD), characterized by chronic activation of glial cells (microglia and astrocytes) and elevated levels of pro-inflammatory mediators in the brain. While initially a protective response, sustained neuroinflammation becomes detrimental and contributes to neurodegeneration. ^{2"TSPO PET imaging (2020)"2020 · DOI 10.1038/s41582-019-0271-2Open reference}

The Neuroinflammatory Response

Microglial Activation

Microglia are the resident immune cells of the brain, derived from yolk sac progenitors. In AD, they undergo dramatic phenotypic changes: ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}

Molecular Triggers: ^{4"Complement and synaptic pruning (2018)"2018 · DOI 10.1016/j.tins.2018.05.008Open reference}

• Amyloid-beta binds to TLRs (TLR2, TLR4), CD36, RAGE

• Tau oligomers activate TLRs and trigger inflammatory responses

• ** DAM (Disease-Associated Microglia) phenotype**

• TREM2 variants increase AD risk 2-4x

Astrocyte Reactivity

Astrocytes adopt a reactive phenotype in AD: ^{5"Cytokines in AD (2019)"2019 · DOI 10.3233/jad-180867Open reference}

• Upregulation of GFAP

• Release of inflammatory mediators

• Impaired glutamate uptake

• Disrupted blood-brain barrier

Inflammatory Cascade

flowchart TD
    A["Abeta Deposition"]  -->  B["Microglial Activation"]
    B  -->  C["Pattern Recognition<br/>Receptors"]
    C  -->  D["TLR2/4<br/>CD36, RAGE<br/>TREM2"]
    D  -->  E["NLRP3<br/>Inflammasome"]
    E  -->  F["Pro-IL-1beta<br/>Pro-IL-18"]
    F  -->  G["IL-1beta, IL-18<br/>Release"]

    B  -->  H["NADPH Oxidase<br/>Activation"]
    H  -->  I["ROS Production"]
    I  -->  J["Oxidative Stress"]
    J  -->  K["Neuronal Damage"]

    G  -->  L["Cytokine Storm"]
    L  -->  M["IL-6<br/>TNF-alpha, IL-1beta"]
    M  -->  N["Synaptic<br/>Dysfunction"]
    N  -->  O["Axonal<br/>Degeneration"]
    O  -->  P["Neuronal Death"]

    Q["Astrocyte<br/>Activation"] -->  R["Complement<br/>System"]
    R  -->  S["C1q, C3b<br/>Opsonization"]
    S  -->  T["Synaptic<br/>Pruning"]
    T  -->  N

    M  -->  U["Tau<br/>Phosphorylation"]
    U  -->  V["NFT Formation"]

    click A "/proteins/amyloid-beta" "Amyloid Beta"
    click B "/cell-types/microglia" "Microglia"
    click D "/mechanisms/trem2-signaling" "TREM2 Signaling"
    click E "/mechanisms/nlrp3-inflammasome" "NLRP3 Inflammasome"
    click L "/mechanisms/cytokine-storm-neuroinflammation" "Cytokine Storm"
    click R "/mechanisms/complement-system-neurodegeneration" "Complement System"
    click N "/mechanisms/synaptic-loss-ad" "Synaptic Loss"

    style A fill:#0a1929,stroke:#333
    style B fill:#3b1114,stroke:#333
    style E fill:#3b1114,stroke:#333
    style L fill:#3b1114,stroke:#333
    style P fill:#3b1114,stroke:#333
    style N fill:#3b1114,stroke:#333
    style V fill:#3b1114,stroke:#333
    style C fill:#3e2200,stroke:#333
    style D fill:#3e2200,stroke:#333
    style F fill:#3e2200,stroke:#333
    style G fill:#3e2200,stroke:#333
    style H fill:#3e2200,stroke:#333
    style I fill:#3e2200,stroke:#333
    style J fill:#3e2200,stroke:#333
    style K fill:#3e2200,stroke:#333
    style M fill:#3e2200,stroke:#333
    style O fill:#3e2200,stroke:#333
    style Q fill:#0a1929,stroke:#333
    style R fill:#3e2200,stroke:#333
    style S fill:#3e2200,stroke:#333
    style T fill:#3e2200,stroke:#333
    style U fill:#3e2200,stroke:#333

Key Inflammatory Mediators

Pro-Inflammatory Cytokines

Chemokines

• CCL2 (MCP-1) - recruits microglia to plaques

• CXCL12/SDF-1 - altered in AD brain

• CX3CL1 (Fractalkine) - neuroprotective, reduced in AD

Complement System

The complement cascade is highly activated in AD: ^{10"Oxidative stress in AD (2010)"2010 · DOI 10.1016/j.jad.2009.08.003Open reference}

• C1q - initiates complement, tags synapses for pruning

• C3 - opsonization, microglial activation

• C3a/C5a - anaphylatoxins, neuroinflammation

Microglial Phenotypes

DAM (Disease-Associated Microglia)

A specialized microglial phenotype characterized by: ^{2"TSPO PET imaging (2020)"2020 · DOI 10.1038/s41582-019-0271-2Open reference}0

• Stage 1: Homeostatic → early DAM (Trem2-independent)

• Stage 2: Late DAM (Trem2-dependent)

• Upregulation of lipid metabolism genes

• Increased phagocytic activity

TREM2 and AD Risk

TREM2 variants are major AD risk factors: ^{2"TSPO PET imaging (2020)"2020 · DOI 10.1038/s41582-019-0271-2Open reference}1

• R47H - ~3x increased risk

• R62H - intermediate risk

• H157Y - risk variant

TREM2 functions: ^{2"TSPO PET imaging (2020)"2020 · DOI 10.1038/s41582-019-0271-2Open reference}2

• Aβ phagocytosis

• Microglial survival

• Lipid metabolism

• Inflammatory response modulation

Genetic Evidence

Neuroinflammation and Other Pathologies

Bidirectional Amyloid Relationship

• Aβ activates microglia → inflammation → more Aβ production

• Chronic inflammation impairs Aβ clearance

• Inflammatory cytokines increase APP expression

Tau and Inflammation

• IL-1β activates GSK-3β → tau phosphorylation

• Inflammation accelerates tau spreading

• Tau aggregates activate microglia

Synaptic Loss

• C1q tags synapses for complement-mediated pruning

• TNF-α reduces synaptic function

• IL-1β impairs LTP

Biomarkers

CSF Markers

• IL-6 - elevated in AD

• YKL-40 (chitinase) - microglial activation

• sTREM2 - soluble TREM2, disease stage-dependent

PET Imaging

• TSPO PET - measures microglial activation

• 11C-PK11195 - first-generation ligand

• 18F-GE-180 - second-generation

Therapeutic Strategies

NSAIDs Controversy

Epidemiological studies suggested reduced AD risk with NSAIDs, but large RCTs failed to show benefit: -可能是治疗时机太晚

• 靶向特异性不足

• 需要个性化方法

Cross-Linking

Neuroinflammation connects to all AD pathological features:

• Amyloid cascade - bidirectional

• Tau pathology - accelerates spreading

• Mitochondrial dysfunction - ROS and energy

• Synaptic loss - complement-mediated pruning

See Also

• Alzheimer’s Disease — Primary neurodegenerative disease

• Parkinson’s Disease — Related neurodegenerative disease

• Amyloid Cascade Pathway - Key AD mechanism

• Tau Pathology - Tau-mediated neurodegeneration

External Links

• PubMed - Biomedical literature

• Nature Reviews Neuroscience - Review articles

The Blood-Brain Barrier in Neuroinflammation

The blood-brain barrier (BBB) plays a critical role in neuroinflammation in AD. BBB dysfunction allows peripheral immune cells and molecules to enter the brain ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}2.

BBB Breakdown in AD

BBB changes in AD include:

• Endothelial dysfunction: Reduced tight junction proteins

• Pericyte loss: Compromised barrier integrity

• Astrocyte end-feet damage: Impaired neurovascular coupling

• Transcytosis increase: Enhanced nanoparticle permeation

Peripheral Immune Cell Infiltration

BBB breakdown enables peripheral immune cell entry:

• T lymphocytes: CD4+ and CD8+ T cells found in AD brain

• Monocytes: Contribute to microglial pool

• B cells: Rare but present in some cases

• NK cells: May have cytotoxic effects

Aβ-Vascular Interactions

Amyloid affects cerebral vasculature:

• Cerebral amyloid angiopathy (CAA): Aβ in vessel walls

• Vessel stiffness: Reduced compliance

• Impaired clearance: Aβ drainage受阻

• Hemodynamic changes: Reduced cerebral blood flow

Neuroinflammation and Oxidative Stress

Inflammation and oxidative stress form a vicious cycle in AD ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}3.

ROS Production in Inflammation

Inflammatory cells generate reactive oxygen species:

• NADPH oxidase: Major ROS source in microglia

• Mitochondrial ROS: Electron leak during inflammation

• Nitric oxide synthase: Produces NO and peroxynitrite

• Xanthine oxidase: Uric acid metabolism ROS

Oxidative Damage Consequences

ROS causes macromolecule damage:

• Lipid peroxidation: Membrane damage, lipid rafts altered

• Protein oxidation: Carbonyl groups, misfolding

• DNA damage: 8-OHdG formation, repair overload

• RNA oxidation: mRNA dysfunction

Antioxidant Defenses

Endogenous antioxidants are overwhelmed:

• Glutathione: Depleted in AD brain

• SOD/Catalase: Impaired function

• Nrf2 pathway: Dysregulated antioxidant response

• Mitochondrial antioxidants: Reduced efficacy

Inflammasome Activation

The NLRP3 inflammasome is a key driver of neuroinflammation ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}4.

Inflammasome Components

• NLRP3: Pattern recognition receptor

• ASC: Adaptor protein

• Caspase-1: Protease that activates cytokines

Activation Triggers

• Aβ crystals: Direct activation

• ATP: P2X7 receptor activation

• ROS: Mitochondrial DAMPs

• Urinary crystals: Amyloid deposits

Downstream Effects

• IL-1β maturation: Pro-inflammatory cytokine activation

• IL-18 release: IFN-γ stimulating

• Pyroptosis: Inflammatory cell death

• Amplification loop: Chronic inflammation

Astrocyte-Neuron Interactions

Astrocytes play complex roles in neuroinflammation ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}5.

Reactive Astrocytes

Astrocyte reactivity in AD:

• GFAP upregulation: Classic marker

• A1 phenotype: Neurotoxic reactive astrocytes

• A2 phenotype: Potentially protective

• S100B release: Pro-inflammatory effects

Metabolic Support Loss

Inflammation impairs astrocyte functions:

• Glutamate uptake: Excitotoxicity

• Lactate production: Energy failure

• Potassium buffering: Dysregulation

• Water balance: Edema susceptibility

Neurovascular Unit Dysfunction

Astrocytes in the neurovascular unit:

• Regulation of cerebral blood flow: Impaired

• BBB maintenance: Compromised

• Aβ clearance: Reduced

• Angiogenesis: Abnormal responses

Sex Differences in Neuroinflammation

Neuroinflammation shows sex-based differences in AD ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}6.

Female Susceptibility

Women show:

• Higher microglial activation: Post-mortem studies

• More pronounced inflammation: Biomarker studies

• Hormonal modulation: Estrogen anti-inflammatory effects

• Genetic factors: Sex-specific genetic architecture

Male Patterns

Men show:

• Different cytokine profiles: Some studies

• Microglial morphology differences: Age-related

• Autoimmune comorbidity effects: Variable

Chronobiology of Inflammation

Inflammatory processes show circadian regulation ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}7.

Inflammatory Rhythms

• IL-6 peaks: Nighttime in humans

• TNF-α: Circadian oscillation

• Microglial surveillance: Time-of-day variation

• Aβ production: Diurnal pattern

Sleep and Inflammation

Bidirectional relationship:

• Sleep deprivation: Increases inflammation

• AD pathology: Disrupts sleep

• Microglial activation: Sleep-wake dependent

• Therapeutic implications: Sleep interventions

Epigenetic Regulation of Inflammation

Inflammation is epigenetically regulated ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}8.

DNA Methylation

• Inflammatory genes: Hypomethylated in AD

• TREM2: Methylation changes

• Genome-wide: Altered patterns

Histone Modifications

• Histone acetylation: Pro-inflammatory gene activation

• HDAC inhibitors: Potential therapy

• H3K27ac: Enhanced inflammatory response

Non-coding RNAs

• miR-155: Pro-inflammatory microRNA

• miR-146a: Anti-inflammatory, dysregulated

• lncRNAs: Inflammatory regulation

Neuroinflammation and Neurogenesis

Chronic inflammation impairs neurogenesis ^{3Sarlus & Heneka, Microglia in Alzheimer's disease (2017)2017 · DOI 10.1177/1073858417697990Open reference}9.

Adult Neurogenesis

• Hippocampal niche: Dentate gyrus

• Impaired in AD: Reduced proliferation

• Inflammatory mediators: Anti-neurogenic

• Therapeutic potential: Inflammation reduction

Inflammatory Barriers

• Cytokine effects: Directly inhibit neurogenesis

• Microglial phagocytosis: Engulf neural precursors

• Niche inflammation: Disrupted environment

• Vascular changes: Impaired niche function

Metabolic Inflammation in AD

Metabolic dysfunction and inflammation are linked ^{4"Complement and synaptic pruning (2018)"2018 · DOI 10.1016/j.tins.2018.05.008Open reference}0.

Insulin Resistance

• Brain insulin resistance: Type 3 diabetes concept

• Inflammatory signaling: IRS1 dysfunction

• Aβ-insulin interaction: Competitive clearance

• Therapeutic approaches: Insulin sensitizers

Lipid Metabolism

• APOE effects: Lipid transport inflammation

• Fatty acids: Pro/anti-inflammatory

• Lipid rafts: Signaling platform alterations

• Eicosanoids: Prostaglandin leukotriene balance

Future Therapeutic Directions

Multi-target Approaches

• Combination therapy: Multiple inflammatory pathways

• Personalized medicine: Patient-specific inflammation profiles

• Timing considerations: Early intervention importance

• Biomarker-driven: Patient selection

Emerging Targets

• TREM2 modulation: Agonists in development

• CD33 inhibition: Genetic validation

• NLRP3 blockers: Clinical trials ongoing

• Microglial repopulation: CSF1R approaches

Conclusion

Neuroinflammation in AD represents a complex, multi-cellular process that both drives and is driven by other pathological features. Understanding the bidirectional relationships between inflammation, amyloid, tau, and synaptic dysfunction provides crucial insights for developing effective therapeutic interventions. As research advances, targeting specific inflammatory pathways while preserving beneficial immune functions remains a key challenge and opportunity in AD therapy.

Clinical Translation and Therapeutic Implications

Current Therapeutic Approaches

The translation of neuroinflammatory mechanisms into clinical therapies has proven challenging, with multiple approaches evaluated in clinical trials ^{4"Complement and synaptic pruning (2018)"2018 · DOI 10.1016/j.tins.2018.05.008Open reference}1.

Anti-Cytokine Therapies

Targeting pro-inflammatory cytokines represents a direct approach:

• IL-1β inhibition: Anakinra (IL-1 receptor antagonist) has been tested in small AD trials with mixed results. The challenge lies in timing—blocking IL-1β too late may not reverse established pathology.

• TNF-α inhibition: Etanercept (TNF receptor-Fc fusion) showed promise in pilot studies but failed in larger trials. Perispinal delivery remains investigational.

• IL-6 signaling: Tocilizumab (anti-IL-6R) is being evaluated for its potential to modulate neuroinflammation in AD patients.

Microglial Modulation

Modulating microglial function rather than broadly suppressing inflammation shows promise:

• TREM2 agonism: Anti-TREM2 antibodies (e.g., from Genentech, AbbVie) are in early-phase trials aiming to enhance microglial phagocytosis of Aβ plaques. The gantenerumab and remibrutinib programs have shown target engagement in Phase 1/2 studies.

• CSF1R inhibitors: PLX5622 (Plexxikon) depletes microglia in animal models but raises concerns about removing beneficial microglial functions. Clinical trials in AD are ongoing.

• CD33 inhibition: Genetic evidence supports CD33 as an AD risk gene; anti-CD33 antibodies are in preclinical development.

NLRP3 Inflammasome Inhibitors

The NLRP3 inflammasome is a key driver of neuroinflammation:

• MCC950: A potent NLRP3 inhibitor showed efficacy in animal models but failed in early clinical trials due to liver toxicity. Next-generation inhibitors are in development.

• Dapansutrile (OLT1177): An oral NLRP3 inhibitor has completed Phase 1/2 trials in cardiovascular disease and is being evaluated for neurodegenerative applications.

• Natural compounds:Quercetin and other flavonoids show NLRP3-modulating activity in preclinical models.

Biomarker Development

Translational biomarkers enable patient selection and monitor therapeutic response ^{4"Complement and synaptic pruning (2018)"2018 · DOI 10.1016/j.tins.2018.05.008Open reference}2.

CSF Inflammatory Markers

• IL-1β: Elevated in AD vs. controls; correlation with cognitive decline

• IL-6: Predicts progression from MCI to AD

• YKL-40: Microglial activation marker; tracks with disease severity

• sTREM2: Soluble TREM2 reflects microglial activity; bidirectional relationship with disease stage

• Neurofilament light chain (NfL): Axonal damage marker; responds to anti-inflammatory treatment

Blood-Based Biomarkers

• IL-6, TNF-α: Elevated in AD; potential for screening

• GFAP: Astrocyte activation; emerging blood marker

• p-tau/total tau ratio: Differentiates AD from other dementias

PET Imaging

• TSPO PET: Measures microglial activation in vivo. First-generation ligands (11C-PK11195) showed increased binding in AD. Second-generation tracers (18F-GE-180, 18F-DPA-714) offer improved kinetics.

• FDG-PET: Metabolic imaging complements inflammatory markers

Clinical Trials Overview

Major clinical trials targeting neuroinflammation in AD:

Therapeutic Implications

Timing of Intervention

A critical challenge is identifying the optimal intervention window:

• Preclinical stage: Anti-inflammatory approaches may prevent disease onset in at-risk individuals

• MCI stage: May represent the optimal window for disease-modifying therapies

• Moderate dementia: Aggressive anti-inflammatory approaches may be too late

Combination Approaches

Given the multifactorial nature of AD, combination therapies are logical:

• Anti-amyloid + anti-inflammatory: Lecanemab + NLRP3 inhibitor

• Anti-tau + immunomodulation: Anti-tau antibodies + TREM2 modulators

• Metabolic + anti-inflammatory: Intranasal insulin + anti-cytokine therapy

Personalized Medicine

Patient selection based on inflammatory biomarkers:

• TREM2 variant carriers: May benefit from TREM2 agonism

• High inflammatory profile: Prioritize anti-inflammatory approaches

• APOE4 carriers: May have increased inflammatory response

Patient Impact and Clinical Relevance

Quality of Life Effects

Neuroinflammation directly impacts patient outcomes:

• Cognitive function: Inflammatory cytokines impair synaptic plasticity and memory

• Behavioral symptoms: Neuroinflammation contributes to agitation, depression, and psychosis

• Functional decline: Inflammation correlates with activities of daily living (ADL) deterioration

Caregiver Burden

Managing neuroinflammation-related symptoms:

• Agitation management: Anti-inflammatory approaches may reduce neuropsychiatric symptoms

• Sleep disturbances: Inflammation disrupts circadian rhythms; treating inflammation may improve sleep

• Daily functioning: Reducing inflammation may preserve functional abilities longer

Challenges and Future Directions

Key Challenges

Emerging Approaches

Future Directions

• Early intervention- Biomarker-driven trials: Enriching trials with patients sho- Combination therapies: Simultaneous